Total Funding
23
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
222030
Tocagen is a biopharmaceutical company developing gene therapy products for the treatment of cancer.
Acquired by 
Forte Biosciences
- Nicholas A. Boyle: Vice President, Corporate Strategy and Business Development
- Mark Foletta: Executive Vice President and Chief Financial Officer
About the Company
Tocagen is a biopharmaceutical company, engages in the discovery, development, and commercialization of products for the treatment of cancer. It develops gene therapy products for treating primary tumors and metastatic diseases. The company's products comprise Prodrug Activator product candidates for treating glioblastoma multiforme; and
immunotherapeutic product candidates for treating metastatic malignant melanoma.
Tocagen was founded in 2007 and is based in San Diego, California.
